Aldeyra 报告 ADX-629 在酒精相关肝炎中的 2 期积极顶线数据

ADX-629 达到主要目标，在 4 名患者的 2 期试验中显示 MELD 评分、甘油三酯和 CRP 较基线有统计学显著改善。Aldeyra 正在停止 ADX-629 的进一步开发，并将资源转向下一代 RASP 调节剂 ADX-248 和 ADX-246，将现金储备延长至 2027 年下半年。

关键事实

申报时间: 2025年10月28日 11:00
事件: 顶线结果
方向: 积极
公司: ALDXAldeyra
资产: ADX-629
来源: SEC 8-K
可信度: 有来源
患者: 4
现金储备: 2027年下半年
CRP水平 p: <0.0001
MELD评分 p: 0.001
甘油三酯水平 p: <0.0001

来源摘录

EX-99.1 2 aldx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 News Release Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules • Relative to Baseline, Signal-Finding Molecule ADX‑629 Demonstrated Statistically Significant Improvement in Liver Function in Patients with Alcohol-Associated Hepatitis • RASP Modulator Product Candidate Pipeline Focused on ADX‑248 and ADX‑246 for Dermatologic, Metabolic, and Retinal Immune-Mediated Diseases • Cash Runway Extended into the Second Half of 2027 Lexington, Mass. October 28, 2025 – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed t

SEC 8-K